FDC LimitedQ2 FY27 Results & Financial Update
FDC Limited: Q2 FY27 consolidated results and company financials – revenue ₹572.14 Cr, PAT ₹49.06 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
FDC price & chart
Market price₹374.60
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore FDC Q2 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
FDC Limited recorded consolidated revenue from operations of INR 572.14 crore for the quarter ended September 30, 2026, alongside total income of INR 590.08 crore.
Revenue contracted sequentially compared to the preceding quarter ended June 30, 2026, where revenue stood at INR 667.69 crore and total income reached INR 715.35 crore.
Profit before tax (PBT) for Q2 FY27 was reported at INR 65.41 crore, reflecting a notable contraction from INR 174.70 crore in the previous quarter.
Profit after tax (PAT) followed a similar sequential trajectory, coming in at INR 49.06 crore compared to INR 132.49 crore in Q1 FY27, resulting in a PAT margin of 8.57% for the current quarter.
Basic and diluted earnings per share (EPS) for the quarter stood at INR 3.01, down from INR 8.14 in the preceding quarter.
The bottom line was affected by operating cost movements and specific provisions recorded during the period, with total provisions reaching INR 36.44 crore.
Total expenses and tax outlays of INR 16.35 crore tempered earnings, while finance costs remained modest at INR 0.84 crore.
FDC Limited reported consolidated revenue from operations of INR 572.14 crore for the quarter ended September 30, 2026 (Q2 FY27), reflecting a decrease compared to the preceding quarter (Q1 FY27) where revenue stood at INR 667.69 crore.
01 · Business model
What does FDC do?
FDC Limited is an established pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs).
The company's commercial portfolio covers anti-infectives, gastrointestinal treatments, ophthalmics, vitamins, and various therapeutic segments distributed across domestic and international markets.
FDC operates its business model through dedicated manufacturing facilities designed to meet regulatory compliance standards for both domestic branded generics and international export markets.
02 · Financial snapshot
Current quarter vs the available comparable
| Metric | Q2 FY27 | Previous quarter |
|---|---|---|
| Revenue from operations | ₹572.14 Cr | ₹667.69 Cr |
| Total income | ₹590.08 Cr | ₹715.35 Cr |
| Profit before tax | ₹65.41 Cr | ₹174.70 Cr |
| Profit after tax | ₹49.06 Cr | ₹132.49 Cr |
| EPS | ₹3.01 | ₹8.14 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 8.6% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 11.4% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹17.94 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
The company generated consolidated revenue of INR 572.14 crore and total income of INR 590.08 crore during Q2 FY27.
Other income contributed INR 17.94 crore to the total income pool during the quarter under review.
Revenue is generated primarily through the sale of pharmaceutical formulations across domestic and international markets.
What drove margins
PAT margin contracted to 8.57% in Q2 FY27 from 19.84% in Q1 FY27, reflecting lower operating leverage and higher provisions during the quarter.
Depreciation and amortisation expenses were reported at INR 15.98 crore, while finance costs remained low at INR 0.84 crore.
The company recorded provisions amounting to INR 36.44 crore during the quarter, impacting bottom-line profitability.
Tax expenses for the quarter stood at INR 16.35 crore against a PBT of INR 65.41 crore.
04 · Items worth noticing
The line items that can distort a quick read
The company recorded provisions amounting to INR 36.44 crore during the quarter ended September 30, 2026.
The company reported provisions of INR 36.44 crore for the quarter.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Statutory Filing Disclosure
The financial results for Q2 FY27 were filed under Indian Accounting Standards (Ind AS) on a consolidated basis via official exchange channels.
Reported update
Filing Submission
The financial results for Q2 FY27 were submitted through an official XBRL filing on October 27, 2026.
06 · Previous-quarter changes
What changed since the previous quarter
Revenue decreased from INR 667.69 crore in Q1 FY27 to INR 572.14 crore in Q2 FY27, while PAT moderated from INR 132.49 crore to INR 49.06 crore over the same timeframe.
Revenue from operations decreased from INR 667.69 crore in Q1 FY27 to INR 572.14 crore in Q2 FY27.
Net profit after tax decreased from INR 132.49 crore in Q1 FY27 to INR 49.06 crore in Q2 FY27.
07 · Key Q&A
The quarter, answered directly
What does FDC do?
FDC Limited is an established pharmaceutical company engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs).
What is the clearest takeaway from Q2 FY27?
FDC Limited recorded consolidated revenue from operations of INR 572.14 crore for the quarter ended September 30, 2026, alongside total income of INR 590.08 crore.
What drove revenue or demand?
The company generated consolidated revenue of INR 572.14 crore and total income of INR 590.08 crore during Q2 FY27.
What mattered most for margins or profitability?
PAT margin contracted to 8.57% in Q2 FY27 from 19.84% in Q1 FY27, reflecting lower operating leverage and higher provisions during the quarter.
What changed operationally beyond the headline numbers?
The financial results for Q2 FY27 were filed under Indian Accounting Standards (Ind AS) on a consolidated basis via official exchange channels.
What should the next disclosure help confirm?
Track upcoming financial results and segment revenue performance in future exchange filings to evaluate operational recovery.
08 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
09 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarterly Disclosures: Track upcoming financial results and segment revenue performance in future exchange filings to evaluate operational recovery.
- 02
Subsequent Quarter Performance: Track revenue and margin recovery in the upcoming quarterly filing.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.